



Please Direct All Correspondence to Customer Number 30,313

ZIW

### TRANSMITTAL LETTER

### INFORMATION DISCLOSURE STATEMENT


Applicant : Goddard, et al.  
 App. No : 10/063,587  
 Filed : May 3, 2002  
 For : SECRETED AND TRANSMEMBRANE  
 POLYPEPTIDES AND NUCLEIC ACIDS  
 ENCODING THE SAME  
 Examiner : Claire M. Kaufman  
 Art Unit : 1646

#### CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

July 7, 2005

(Date)

  
AnneMarie Kaiser, Reg. No. 37,649

**Mail Stop Amendment**  
 Commissioner for Patents  
 P.O. Box 1450  
 Alexandria, VA 22313-1450

Dear Sir:


Enclosed for filing in the above-identified application are:


(X) An Information Disclosure Statement and PTO/SB/08 equivalent listing references for consideration:

- (X) Listing 42 references.
- (X) Enclosing 29 references.

(X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.

(X) Return prepaid postcard.

  
AnneMarie Kaiser  
Registration No. 37,649  
Attorney of Record



## INFORMATION DISCLOSURE STATEMENT

Applicant : Goddard, et al.  
App. No : 10/063,587  
Filed : May 3, 2002  
For : SECRETED AND TRANSMEMBRANE  
Examiner : POLYPEPTIDES AND NUCLEIC ACIDS  
Art Unit : ENCODING THE SAME  
Examiner : Claire M. Kaufman  
Art Unit : 1646

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application is a PTO/SB/08 Equivalent listing 42 references to be considered by the Examiner. Also enclosed are 29 foreign patent references and/or non-patent literature as listed on the Information Disclosure Statement.


This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required. If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: July 7, 2005

By: AnneMarie Kaiser  
AnneMarie Kaiser  
Registration No. 37,649  
Attorney of Record  
Customer No. 30,313  
(619) 235-8550



INFORMATION DISCLOSURE STATEMENT BY APPLICANT	
(Multiple sheets used when necessary)	
SHEET 1 OF 3	

Application No.	10/063,587
Filing Date	May 3, 2002
First Named Inventor	Goddard, et al.
Art Unit	1646
Examiner	Claire M. Kaufman
Attorney Docket No.	GNE.3230R1C61

## U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
	1	6,025,156	02-15-2000	Gwynn, et al.	
	2	6,124,433	09-26-2000	Falb, et al.	
	3	6,156,500	12-05-2000	Falb, Dean	
	4	6,162,604	12-19-2000	Jacob, Chaim O.	
	5	6,228,582	05-08-2001	Rodier, et al.	
	6	6,395,306	05-28-2002	Cui, et al.	
	7	6,414,117	07-02-2002	Levinson, D. A.	
	8	6,465,185	10-15-2002	Goldfine, et al.	
	9	6,498,235	12-24-2002	Sheppard, et al.	
	10	6,562,343	05-13-2003	Levinson, D. A.	
	11	6,645,499	11-11-2003	Lal, et al.	
	12	6,730,502	05-04-2004	Van Hijum, et al.	
	13	6,737,522	05-18-2004	Sundick, et al.	

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
	14	ALBERTS, et al. 1994. <i>Molecular Biology of the Cell</i> , 3rd Edition, pp. 403-404, 453. New York: Garland Publishing.	
	15	ALBERTS, et al. 2002. <i>Molecular Biology of the Cell</i> 4th Edition, pp. 302, 363-364, 379, 435. New York: Garland Publishing.	
	16	ALLMAN, et al. 1996. BCL-6 expression during B-cell activation. <i>Blood</i> , 87(12):5257-5268.	
	17	CHEN, et al. 2002. Discordant Protein and mRNA Expression in Lung Adenocarcinomas. <i>Molecular &amp; Cellular Proteomics</i> 1.4, 304-313.	
	18	FU, et al. 1996. Translational regulation of human p53 gene expression. <i>The EMBO Journal</i> , Vol. 15, No. 16, pp. 4392-4401.	
	19	GÖKMEN-POLAR, et al., February 2001, Elevated Protein Kinase C $\beta$ II Is an Early Promotive Event in Colon Carcinogenesis, <i>Cancer Research</i> , Vol. 61, pp.1375-1381.	
	20	GRIMALDI, et al. 1989. The t(5;14) chromosomal translocation in a case of acute lymphocytic leukemia joins the interleukin-3 gene to the immunoglobulin heavy chain gene. <i>Blood</i> , 73(8):2081-2085.	

Examiner Signature	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <small>11 2005</small> <small>Multiple sheets used when necessary)</small> <small>SHEET 2 OF 3</small>		Application No.	10/063,587
		Filing Date	May 3, 2002
		First Named Inventor	Goddard, et al.
		Art Unit	1646
		Examiner	Claire M. Kaufman
		Attorney Docket No.	GNE.3230R1C61

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
	21	GYGI, et al. Mar. 1999. Correlation between Protein and mRNA Abundance in Yeast. <i>Molecular and Cellular Biology</i> , 1720-1730.	
	22	HANASH, S. 2003. Making sense of microarray data to classify cancer. <i>The Pharmacogenomics Journal</i> , 3:308-311.	
	23	HANASH, S. March 2005. Integrated global profiling of cancer. <i>Nature Reviews, Applied Proteomics Collection</i> , pp. 9-14.	
	24	HANCOCK, W. S. 2004. Do We Have Enough Biomarkers? <i>Journal of Proteome Research</i> , 3(4):685.	
	25	HANNA, et al. Aug. 1999. HER-2/neu breast cancer predictive testing. <i>Pathology Associates Medical Laboratories</i> .	
	26	HAYNES, et al., 1998. Proteome analysis: Biological assay or data archive? <i>Electrophoresis</i> , Vol. 19, pp. 1862- 1871.	
	27	HU, et al. 2003. Analysis of Genomic and Proteomic Data Using Advanced Literature Mining. <i>Journal of Proteome Research</i> , Vol. 2, pp. 405-412.	
	28	HYMAN et al. Nov. 2002. Impact of DNA Amplification of Gene Expression Patterns. <i>Cancer Research</i> , 62:6240-6245.	
	29	JANG A. Hill RP, Sept. 1997. An examination of the effects of hypoxia, acidosis, and glucose starvation on the expression of metastasis-associated genes in murine tumor cells. <i>Clin. Exp. Metastasis</i> 15(5): pp. 469-483	
	30	KONOPKA, et al. June 1986. Variable Expression of the Translocated c-abl Oncogene in Philadelphia-Chromosome-Positive B-Lymphoid Cell Lines from Chronic Myelogenous Leukemia Patients, <i>National Academy of Sciences of the United States of America</i> , Vol. 83, No. 11, pp. 4049-4052	
	31	LEWIN, B. 1994. Oncogenes: Gene Expression and Cancer, Chap. 39, pp.1196-1201. <i>Genes V</i> . New York: Oxford University Press.	
	32	LEWIN, B. 1997. Regulation of Transcription, Chap. 29, pp. 847-848. <i>Genes VI</i> . New York: Oxford University Press.	
	33	MEEKER, et al. 1990. Activation of the interleukin-3 gene by chromosome translocation in acute lymphocytic leukemia with eosinophilia. <i>Blood</i> , 76(2):285-289.	
	34	MERIC, et al. 2002. Translation initiation in cancer: A novel target for therapy. <i>Molecular Cancer Therapeutics</i> , 1:971-979.	
	35	OHARA, et al. 2001. Directional cDNA library construction assisted by the in vitro recombination reaction. <i>Nucleic Acids Research</i> , Vol. 29, No e22, pp.1-8.	
	36	ØRNTOFT, et al. 2002. Genome-wide study of gene copy numbers, transcripts, and protein levels in pairs of non-invasive and invasive human transitional cell carcinomas. <i>Molecular &amp; Cellular Proteomics</i> , 1:37-45.	
	37	POLLACK, et al. 2002. Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. <i>PNAS</i> , 99(20):12963-12968.	

Examiner Signature	Date Considered
<small>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>	

<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <small>O P E S U C A</small> <small>JUL 11 2005 (Multiple sheets used when necessary)</small> <small>SHEET 3 OF 3</small>		Application No.	10/063,587
		Filing Date	May 3, 2002
		First Named Inventor	Goddard, et al.
		Art Unit	1646
	Examiner	Claire M. Kaufman	
		Attorney Docket No.	GNE.3230R1C61

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>1</sup>
	38	POWELL, et al. Oct. 1998. Expression of cytochrome P4502E1 in human liver: assessment by mRNA, genotype and phenotype. <i>Pharmacogenetics</i> , Vol.5: pp. 411-421.		
	39	SINGLETON, et al. 1992. Clinical and pathologic significance of the c-erbB-2 (HER-2/neu) oncogene. <i>Pathol. Annu.</i> , 1(27):165-190.		
	40	VALLEJO, et al. Dec. 2000. Evidence of tissue-specific, post-transcriptional regulation of NRF-2 expression. <i>Biochimie</i> 82(12): 1129-33.		
	41	WANG, et al. 1996. mRNA Differential display: Application in the discovery of novel pharmacological targets. <i>Trends Pharmacol. Sci.</i> , 17(8):276-279.		
	42	ZHIGANG, et al. 2004. Prostate stem cell antigen (PSCA) expression in human prostate cancer tissues and its potential role in prostate carcinogenesis and progression of prostate cancer. <i>World Journal of Surgical Oncology</i> , 2:13.		

1780364/jk  
062105

Examiner Signature	Date Considered
<small>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>	

<sup>T<sup>1</sup></sup> - Place a check mark in this area when an English language Translation is attached.